Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JCXH-212
- Development stage
- Phase 1
- Lead developer
- Immorna
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intramuscular
01
Overview
JCXH-212 is a self-replicating RNA (srRNA) cancer vaccine designed to encode patient-specific tumor neoantigens. It functions as an immunostimulant and antineoplastic agent by inducing immune responses against tumor cells. The vaccine is classified as a therapeutic mRNA vaccine and targets interleukin-12 (IL-12), acting as an IL-12 modulator to enhance anti-tumor immunity. Developed for the treatment of advanced malignant solid tumors, it is currently in Phase 1/2 clinical trials. The developer and manufacturer is Jiachen Xihai (Hangzhou) Biotechnology Co., Ltd., also known as Immorna Biotherapeutics[1][2][3][4][8].
02
Targets
IL-12R (Interleukin-12 receptor)IL12 (Interleukin-12)
Beyond the preview
Go deeper on JCXH-212.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JCXH-212.